Uniquity Bio is the latest such company, unveiled by Blackstone Life Sciences on Wednesday with $300 million and a phase 2-stage lead asset. Solrikitug, an anti-TSLP antibody in-licensed from Merck & Co., was just given the green light by the FDA for two looming studies in chronic obstructive pulmonary disease (COPD) and asthma, respectively. And Blackstone’s head of life science investments suggests the pipeline may soon grow.
Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation
How does Bill Meury celebrate a $14 billion merger? With a new post at a Blackstone-founded biotech.
Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program
Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program
Hot off an FDA approval for its Pompe disease combo treatment, Amicus Therapeutics has reeled in a major investor.
Blackstone Life Sciences’ $250 million bet on an ex-Novartis drug candidate has racked up another phase 2 win. The data show Anthos Therapeutics’ abelacimab significantly cut bleeding compared to Bayer and Johnson & Johnson’s Xarelto, adding to evidence that the biotech's candidate can treat thrombosis without affecting hemostasis.
Blackstone sets its sights on buying out Hamieds from Cipla
Investor Blackstone Life Sciences is paying Sutro Biopharma $140 million cash and throwing in another potential $250 million in biobucks in exchange for royalties on possible future sales of Vaxcyte’s products.
Alembic Pharma gets USFDA nod for generic drug to treat breast cancer